Holen Sie sich die Stockscreener-App
18.78
6.05%
-1.21
Handel nachbörslich:
18.81
0.03
+0.16%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead - insights.citeline.com
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives - Investor's Business Daily
Arrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake - MSN
Arrowhead Pharmaceuticals Inc. Attempts Reversal From Key Support2025 Winners & Losers & Risk Managed Investment Entry Signals - sundaytimes.kr
Arrowhead Pharmaceuticals Advances Plozasiran Study for Hypertriglyceridemia - TipRanks
Sarepta Sells Arrowhead Stake to Fund Milestone Payment - TradingView
Arrowhead Pharmaceuticals stock falls after Sarepta sells shares - Investing.com
Arrowhead Pharmaceuticals stock falls after Sarepta sells shares By Investing.com - Investing.com UK
Sarepta offloads Arrowhead stake to fund milestone payment - The Pharma Letter
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics - BioSpace
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sarepta Sells Arrowhead Stock, Activates $100M Milestone Payment - AInvest
Sarepta sells $174 million in Arrowhead stock, triggers $100 million milestone - StreetInsider
Sarepta Therapeutics Sells Arrowhead Stake for $174mln, Advances RNAi Collaboration - AInvest
Sarepta Therapeutics to Pay Arrowhead Pharmaceuticals $100 Million Milestone in Cash and Stock - AInvest
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment - Sarepta Therapeutics
Arrowhead Pharmaceuticals Soars 11% Intraday: What's Fueling This Biotech Breakout? - AInvest
Healthcare Analysts Offer Insights on Trevi Therapeutics, DENTSPLY SIRONA, and Arrowhead Pharmaceuticals. - AInvest
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2025 Earnings Call Transcript - Insider Monkey
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt? - 富途牛牛
Arrowhead Pharmaceuticals’ Earnings Call Highlights Strategic Progress - TipRanks
Arrowhead Pharmaceuticals Advances RNAi Therapeutics Pipeline - TipRanks
Arrowhead Pharma's Analyst Rating and Price Target Maintained at $60.00 - AInvest
RBC Capital Adjusts Price Target for Arrowhead Pharma to $38.00 from $40.00, Maintaining "Outperform" Rating - AInvest
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Arrowhead reports Q3 EPS ($1.26), consensus ($1.10) - TipRanks
ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS - Research Tree
Is Arrowhead Pharmaceuticals Inc. trending in predictive chart modelsStock Market Watch with Smart Filters - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Arrowhead Pharmaceuticals: A High-Conviction Biotech Play with Multi-Billion-Dollar Potential - AInvest
Quoin (QNRX) Q2 Loss Beats Estimates - AOL.com
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $29 to $45 - 富途牛牛
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Arrowhead Pharma stock price target lowered to $21 at Leerink Partners - Investing.com Canada
Arrowhead Pharmaceuticals: Balancing Promising Launch Preparations with Pipeline Uncertainties - TipRanks
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts - Investing.com
RBC Trims Price Target on Arrowhead Pharmaceuticals to $38 From $40, Keeps Outperform, Speculative Risk - MarketScreener
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts By Investing.com - Investing.com Canada
Arrowhead (ARWR) Q3 Revenue Drops 41% - AOL.com
Arrowhead Pharmaceuticals: Navigating a Narrowing Loss and a Pivotal Regulatory Timeline for Plozasiran - AInvest
Arrowhead Pharmaceuticals Fiscal Q3 Loss Narrows, Reports Revenue - MarketScreener
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2025 Earnings Call Highl - GuruFocus
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Arrowhead Pharmaceuticals: Buy Rating Affirmed on Promising Pipeline and Late-Stage Developments - TipRanks
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript - AOL.com
ARROWHEAD PHARMACEUTICALS Earnings Results: $ARWR Reports Quarterly Earnings | ARWR Stock News - Quiver Quantitative
Arrowhead Pharmaceuticals Q3 Revenue Surpasses Expectations with $27.8mln, Sarepta Milestone Earnings $100mln. - AInvest
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results - Business Wire
Arrowhead Pharmaceuticals shares fall 2.15% intraday as Sarepta Therapeutics reports strong earnings and resumes deliveries. - AInvest
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Arrowhead Pharmaceuticals (ARWR) Prepares for Q3 Earnings Report - GuruFocus
TR | OpenAI4o Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $16.5 - 富途牛牛
Arrowhead sells rights of Hypertriglyceridemia candidate to Sanofi in Greater China for $265 M - BioSpectrum Asia
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi - Yahoo Finance
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):